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ABSTRACT
Intestinal microbiota play a crucial role in the development of mucosal tolerance and adaptation. Perturbations
in microbiota composition are strongly associated with allergies and asthma in westernized countries. There
has been accumulating evidence that the administration of probiotics, “live microbial supplements that exert a
beneficial effect on human health,” may be effective in the treatment andor prevention of allergic diseases. Al-
though it has been shown that part of the effect of probiotics arises from its interaction with the host immune
system, the precise mechanisms remain to be determined. In addition, future studies are necessary to define
appropriate species and strains, optimum dose, frequency, and duration for the treatment of allergic diseases.
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INTRODUCTION
Intestinal microbiota, which live in symbiosis with the
human body and are major bacterial stimuli received
by neonates after birth, are reported to significantly
affect human conditions and to be essential for the
development and maintenance of the immune sys-
tem.1,2 Recent studies have shown a relationship be-
tween intestinal microbiota and the pathogenesis of
immunological disorders including allergic diseases.3
These observations suggest that a normalization of
intestinal microbiota may lead to an improvement in
allergic diseases. Probiotics are defined as “live mi-
crobial supplements that exert a beneficial effect on
human health,” and have been shown to be effective
in the treatment andor prevention of allergic dis-
eases.4 Some of these effects are mediated by the in-
teraction of probiotics and the immune system. In
this review we focus mainly on interactions of probi-
otics with innate immunity and their potential for
treating allergic diseases.
HUMAN INTESTINAL MICROBIOTA
In the lower intestine of adult humans, the density of
commensal bacteria in the lumen reaches 1012 organ-
isms per gram of intestinal content , with approxi-
mately 400―1,000 species present. The total weight of
microbiota is estimated to be 1 kg. The majority of
the bacterial species are strict anaerobes ( 97% ) ,
whereas only 3% are aerobic (facultative anaerobes).
The most common anaerobic genera in terms of con-
centration within the gastrointestinal tract are Bacter-
oides, Bifidobacterium, Eubacterium, Fusobacterium,
Clostridium and Lactobacillus. Among the aerobes are
the Gram-negative enteric bacteria (Escherichia coli
and Salmonella spp.) and the Gram-positive cocci (En-
terococcus, Staphylococcus and Streptococcus). In addi-
tion to aerobic bacteria, aerobic fungal species, such
as Candida albicans, are also among the normal mi-
crobiota. It should be noted that the composition of
intestinal microbiota changes in accordance with age
(Fig. 1).
ALTERED MICROBIOTA AND DISTURBED
IMMUNITY
It has been shown that alterations in the intestinal mi-
crobiota can influence mucosal immunity and lead to
the development of allergy. Oyama et al. showed that
the administration of kanamycin to neonatal, but not
adult, mice increased the serum levels of total IgG1
and IgE while decreasing the serum IgG2a levels.5
The oral introduction of intestinal bacteria into these
antibiotic-treated mice prevented the upregulation of
basal Th2 responses in the spleen, indicating that the
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Fig. 1 Chronological changes in intestinal flora (Mitsuoka 
T. 1972).
Lactobacillus
Clostridium perfringens 
Birth Weaning Adult Old age
Lo
g 
10
/g
 fe
ce
Bacteroides, Eubacterium, anaerobic cocci 
Bifidobacterium
Escherichia coli, Enterococcus
12
10
8
6
4
2
mechanism involves the perturbation of intestinal mi-
crobiota.6 These results suggest that use of antibiot-
ics during infancy may disturb the intestinal mi-
croflora and inhibit postnatal Th1-type immune matu-
ration, thus resulting in a Th2-polarized immune de-
viation and the development of allergic diseases. Sev-
eral early epidemiological studies have identified a
correlation between early antibiotic use in children
and the subsequent development of allergies andor
asthma. Among anthroposophic children, the use of
antibiotics early in life is significantly associated with
the development of asthma.7 In addition, it was found
that the microbiota of anthroposophic children con-
tain higher levels of lactic acid bacteria than the mi-
crobiota of children who had previously been ex-
posed to antibiotics.8 However, recent studies do not
support the hypothesis that the use of antibiotics in
early life is associated with the subsequent develop-
ment of asthma in childhood, but rather suggest that
frequent antibiotic use in early life is more common
among asthmatic children.9,10 Thus, it is not yet de-
termined that the use of antibiotics in infancy leads to
the development of allergic diseases. Nevertheless,
accumulating data indicate that altered intestinal mi-
crobiota may influence the development of the Th2
response and allergic diseases.
MICROBIOTA IN CHILDREN WITH ALLER-
GIC DISEASES
Several studies , mostly from northern European
countries, indicate that the composition of the intesti-
nal microbiota is different in atopic versus non-atopic
individuals.11-15 Bjorksten et al. reported that allergic
children (as determined by positive skin-prick tests to
common allergens) in Sweden and Estonia harbor in-
creased levels of aerobic microbes and decreased lev-
els of anaerobic microbes, particularly Lactobacillus.11
Isolauri et al. have also reported decreased levels of
Bifidobacterium and a reduction in the number of
Gram-positive organisms among the aerobic popula-
tions in infants with atopic eczema.12 Furthermore,
prospective cohort studies suggest that aberrance in
intestinal microbiota precedes the development of al-
lergic diseases . 13,14 Allergic infants have a lower
prevalence of Bifidobacterium and a reduced ratio of
Bifidobacterium to Clostridium before the develop-
ment of allergic manifestations or positive results of
skin prick testing.13 In another study, infants who de-
veloped allergies were found to harbor lower levels of
Bifidobacterium and Enterococcus but increased levels
of Clostridium and Staphylococcus aureus(Table 1).14
So far, few studies on intestinal microbiota and the
development of allergic diseases in infancy have been
reported from areas other than northern Europe .
Since intestinal microbiota are significantly influ-
enced by genetic and dietary differences,16,17 we per-
formed a prospective cohort study on intestinal mi-
crobiota in a small population in Japan in which in-
fants born in a hospital were followed from birth to 2
years of age. Our data indicate no aberrant composi-
tion of intestinal microbiota at 6 months of age when
some infants developed atopic dermatitis or showed
positive skin tests . However , allergic infants had
higher counts of Bacteroides, a higher prevalence of
yeast-like organisms, and a higher ratio of Bacteroides
to Bifidobacterium at 2 years of age (Fig . 2). This
study suggests that aberrance in intestinal microbiota
does not necessarily precede the development of al-
lergy in early infancy, but may become evident after
weaning. We speculate that abnormalities in intesti-
nal microbiota are not only the cause for the develop-
ment of allergic disease, but also a consequence of
the intestinal environment resulting from allergic in-
flammation (Suzuki S et al. submitted).
CLINICAL EFFECTS OF PROBIOTICS ON
ALLERGIC DISEASES
As mentioned above, aberrance in intestinal micro-
biota may be a cause, result or both of allergic dis-
eases. Nevertheless, a normalization of the intestinal
microbiota may be effective for the treatment of aller-
gic diseases. In fact, recent clinical studies have pro-
vided evidence that probiotic supplementation indeed
has an effect on allergic diseases. Isolauri et al. stud-
ied the treatment of atopic eczema with probiotics in
infants who developed eczema during exclusive
breastfeeding.18 The infants were weaned to a probi-
otic supplemented hydrolyzed formula . After 2
months of treatment, the SCORAD score was signifi-
cantly lower in infants who received either Bifidobac-
terium lactis Bb-12- or Lactobacillus rhamnosus GG-
supplemented formula than in infants who received
unsupplemented hydrolysed formula . The same
authors also showed that the clinical score of atopic
dermatitis improved significantly during a 1-month
study period in infants with food allergy treated with
Lactobacillus rhamunosus GG supplemented hydro-
lysed formula.19 Rosenfedt et al. demonstrated that a
combination of Lactobacillus rhamnosus 19070―2 and
Lactobacillus reuteri DSM 122460 given for 6 weeks
to 1 to 13-year-old children with atopic dermatitis re-
sulted in a more efficient improvement of eczema, al-
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Fig. 2 Ratios of Bacteroides to Bifidobacterium in alergic 
and healthy children at 2 years of age
0
2
4
6
8
10
12
14
16
B
ac
te
ro
id
es
/B
ifi
d
ob
ac
te
riu
m
P ＜ 0.05
Allergic
(n ＝ 6)
Nonallergic
(n ＝ 6)
Table 1 Prevalence of certain species of intestinal microorganisms in healthy and alergic children 
Prevalence (%)(Healthy/Alergic)
Microorganisms
12 months3 months1 month1 week
96/8996/8996/72*96/67*Enterococci
38/4434/5646/56 8/39*Lactobacili
69/22*62/28*69/3950/17*Bifidobacteria
*Statisticaly significant diference (modified from ref. 14)
though the total SCORAD index did not change in
the whole group.20 They also recently reported that
Lactobacillus supplementation leads to a significant
decrease in the frequency of gastrointestinal symp-
toms in food-allergic patients with atopic dermatitis.21
Several studies on the effects of probiotics on aller-
gic rhinitis have been reported. Wang et al. assessed
whether the ingestion of fermented milk containing
Lactobacillus paracasei-33 ( LP-33 ) can improve the
quality of life of patients with perennial allergic rhini-
tis in a randomized, double-blind, placebo-controlled
trial. The results suggest that the ingestion of LP-33-
fortified fermented milk for 30 days can effectively
and safely improve the quality of life of patients with
allergic rhinitis.22 In contrast, Helin et al. reported no
significant effect of probiotic bacteriotherapy with
Lactobacillus rhamnosus GG in teenagers and young
adults who were allergic to birch pollen and apple
food and had intermittent symptoms of atopic allergy
andor mild asthma.23
The effects of probiotics in the prevention of early
atopic disease in children at high risk, i.e. with a fam-
ily history of atopy, were also studied.24 Lactobacillus
rhamnosus GG was given in capsules to mothers daily
for 24 weeks before the expected date of delivery ,
and, after delivery, either to breastfeeding mothers or
children (capsule content mixed with water and given
with a spoon) for 6 months. Most families gave the
capsules to the infants. In a prospective study from
birth, atopic eczema was diagnosed in 46 of 132 (35%)
children at 2 years of age. The frequency of atopic ec-
zema in the probiotic group was half that of the pla-
cebo group (1564 [23%] vs. 3168 [46%]; relative risk
0.51 [95% CI 0.32―0.84]). Of special note, no differ-
ences in skin prick test positivity or total or specific
IgE levels were observed between the placebo and
probiotic groups . These children were evaluated
again at 4 years of age, and atopic eczema was diag-
nosed on the basis of a questionnaire and clinical ex-
amination.25 Fourteen of 53 children who received
Lactobacillus rhamnosus GG had developed atopic ec-
zema compared with 25 of 54 children in the placebo
group, a relative risk of 0.57 and a 95% CI of 0.33―
0.97. Again, no differences in skin prick test reactivity
were found between the groups. Another study indi-
cated that the long-term consumption of milk contain-
ing Lactobacillus rhamnosus GG reduces respiratory
infections in children attending daycare centers.26 Re-
cently, it was reported that repeated oral application
of a non-pathogenic Escherichia coli strain in the early
postnatal period prevented the incidence of allergies
over a long-term (10 and 20 years) study.27 These
data suggest that infants are the main targets for pro-
biotic treatment for the prevention of allergic dis-
eases.
EFFECTS OF PROBIOTICS ON INNATE IM-
MUNE FUNCTION
Studies on the effects of probiotic treatment for aller-
gic diseases have demonstrated that cytokine produc-
tion can be modified by probiotics . Two types of
upregulation of cytokine production have been
shown: Th1 type cytokines such as IFN-gamma and
regulatory cytokines such as interleukin (IL) 10 or
transforming growth factor beta (TGF-beta). Pohja-
vuori et al. reported that Lactobacillus rhamnosus GG
raises IFN-gamma production of PBMC in infants
with cow’s milk allergy and in infants with IgE-
associated dermatitis . 28 Aldinucci et al. gave rhino-
pathic patients either yoghurt or partially skimmed
milk for 4 months and compared cytokine production
between the two groups. They found that cultured
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PBMC from the group fed yoghurt released more
IFN-gamma and less IL-4 compared with the control
group . 29 Interestingly , plasma cytokine levels re-
mained at basal levels. Rosenfeldt et al. also could not
find any change in serum IFN-gamma levels despite
an improvement in atopic dermatitis by treatment
with Lactobacillus rhamnosus 19070―2 and Lactobacil-
lus reuteri DSM 122460. 20 Rautava examined the
amount of TGF-beta2 in the milk of mothers receiv-
ing or not receiving probiotics, and its relationship to
the risk of infants developing atopic eczema during
the first 2 years of life. They found that TGF-beta2
levels in the breast milk of mothers receiving probiot-
ics were higher than in mothers receiving placebo,
and that infants whose mothers received probiotics
had a significantly lower risk of developing atopic ec-
zema than infants whose mothers received the pla-
cebo.30 The same group also showed that oral Lacto-
bacillus rhamnosus GG ingestion for 5 days to 4
weeks could alleviate the clinical symptoms of gastro-
intestinal inflammation and atopic dermatitis, an ef-
fect that is associated with elevated serum levels of
IL-10.31 These data suggest that probiotics increase
both Th1 and regulatory cytokines.
Cytokine production from T lymphocytes in the
adaptive immune system is controlled by innate im-
munity. Thus, the effect of probiotics on innate immu-
nity, such as macrophage and dendritic cells (DCs),
has been studied. The stimulation of human mononu-
clear cells with Lactobacillus rhamnosus GG has been
shown to promote the production of IFN-gamma, IL-
12 and IL-18, the latter two being monocyte-specific
cytokines.32 When the mechanisms of activation were
studied in human monocytes, the activation of NF-κB
and STAT was shown after stimulation with Lactoba-
cillus rhamnosus GG cell wall components . 33 How-
ever, pathogenic bacteria were also found to stimu-
late macrophageDC to produce inflammatory cytoki-
nes in an in vitro study.34 Thus, the differences in the
innate immune responses to probiotics and patho-
genic bacteria are not yet fully clear. Furthermore,
different Lactobacillus species differ in their ability to
induce cytokine expression . Lactobacillus casei is a
strong inducer of IL-12, IL-6 and TNF-alpha together
with maturation surface markers. In contrast, Lacto-
bacillus reuteri appears to be a poor IL-12 inducer and
inhibits cytokine induction and up-regulation of B7-2
induced by other Lactobacillus species . 35 We exam-
ined cytokine production by cord blood monocytes
following stimulation with either Bifidobacterium ado-
lescentis or Bifidobacterium bifidum. The results
showed that the cytokine-inducing activities of these
two Bifidobacterium species differ (Fig. 3). These
findings strongly suggest that different species
strains in probiotics may modify the function of
monocyteDCs differently, and thus modify the char-
acteristics of the immune response that is triggered.
INTERACTION OF PROBIOTICS WITH EPI-
THELIAL CELLS
Intestinal epithelial cells play an important role in the
presentation of oral antigens and also in the regula-
tion of intestinal immune responses. Intestinal micro-
biota have been suggested to be important regulators
of the function and development of immune and epi-
thelial cells. Usually, commensal microbiota coexist
peacefully with us and no inflammation is evoked ,
while the presence of virulence factors on pathogenic
bacteria amplifies inflammatory immune responses.
Although regulatory mechanisms driven by CD4 +
regulatory T cells in the lamina propria are important
for maintaining tolerance to enteric bacteria , 36 it is
likely that other equally important mechanisms con-
trolling innate immunity and inflammation operate at
the level of epithelial cells. Mice deficient in MyD88,
the adapter molecule essential for TLR signaling, fail
to express epithelial hsp25 and hsp72 and are highly
susceptible to experimental inflammatory bowel dis-
ease (IBD) initiated by dextran sodium sulfate, sug-
gesting that through TLR signaling , bacterial flora
may help protect the gut epithelium from nonspecific
damage.37 It has been shown that normal flora induce
the cytoprotective proteins hsp25 and hsp72 in colo-
nic epithelial cells.38 Nonpathogenic microorganisms
in the gut have also been shown to regulate inflam-
mation negatively in other ways . 39,40 Kelly et al.
showed that the nonpathogenic bacterium, Bacteroi-
des thetaiotaomicron targets the transcriptionally ac-
tive NF-κB subunit RelA leading to the activation of
the peroxisome proliferator activated receptor
(PPAR) and a PPAR-dependent anti-inflammatory
mechanism.39 Interestingly, Bacteroides vulgatus did
not produce a similar effect, suggesting a strain differ-
ence. Neish et al. showed that avirulent Salmonella
inhibit the activation of NF-κB in epithelial cells by
blocking the polyubiquitination of phosphorylated
IκB,40 while enteropathogens induce NF-κB activa-
tion of epithelial cells leading to inflammation . 41
These data indicate commensal microbiota have ma-
chinery different from enteropathogenic bacteria to
allow them to coexist with us . In addition to the
mechanisms described above, several other functions
have been reported. For example, commensals may
play a role in the recovery of intestinal epithelia as
suggested by a report on the prevention of cytokine-
induced apoptosis in intestinal epithelial cells in the
presence of Lactobacillus rhamnosus GG.42 This kind
of protection against inflammation-induced injury
may be important in the regulation of the intestinal
immune response when new antigens are encoun-
tered during infancy, or in inflammatory conditions
induced by pathogenic microbes and allergens.
CONCLUSION
How probiotics exert their effects on innate immunity
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Fig. 3 Diference in cytokine-inducing activity of Bifidoba-
cterium adolescentis and Bifidobacterium bifidum. Cord 
blood monocytes were cultured with heat-inactivated bacte-
ria for 24 hours, and TNF-α in the culture supernatant was 
measured using a commercial ELISA kit. 
0
400
800
1200
1600
pg/ml
T
N
F
-α
 in
 t
he
 c
ul
tu
re
 s
up
B. adolescentis
(n＝5)
B. bifidum
(n＝5)
P ＜ 0.05
remains an open question , although accumulating
evidence indicates that probiotics may be an alterna-
tive option for the treatment of allergic diseases .
More precise information is needed about the interac-
tion between commensal microbiota and the innate
immune system. Macrophages and DCs obtain infor-
mation from residential cells in the tissue. It is likely
that probiotics act on the innate immune system
through residential cells , such as epithelial cells ,
rather than by interacting directly with macrophages
and DCs. A recent study has indicated that epithelial
cells and stromal cells in the intestine exert a pro-
found suppressive effect on intestinal macrophages
through the production of TGF-beta as well as
IL-10.43 Future studies will focus on the effects of pro-
biotics on epithelial cells and stromal cells.
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